| ID | 1196 |
| Name of the vaccine | CVD 1208S-122 |
| Microbe | Bacteria |
| Disease name | Bacillary Dysentery (Shigellosis) |
| Name of bacteria | Shigella genus |
| Type of vaccine | Live attenuated |
| Nucleic acid content | DNA |
| Age | 18 to 49 years |
| Description of the vaccine | Combined Shigella-ETEC vaccine. |
| Name of the manufacturer | University of Maryland, Baltimore |
| Name of the manufacturing country | United States |
| Year of manufacture | 2023 |
| Clinical Phase status | Clinical - Phase 1 |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Single dose |
| Mechanism of action | Anti-Shigella LPS IgG, anti-CFA/I antibodies production. |
| Route of administration | Oral |
| Indications | Prevents disease outcomes-weight loss and diarrhoea. |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For enterotoxigenic Escherichia Coli infection. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | 32257392 |
| Clinical trial number | NCT04634513 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|